caa a22 4500 605491410 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0787-6 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0787-6 Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study [Elektronische Daten] [Naotaka Nishiyama, Satoshi Takahashi, Takahiro Mizuno, Teruhisa Uehara, Jiro Hashimoto, Yuichirou Kurimura, Naoya Masumori] Objectives: The aims of this study were to clarify the frequency and prognosis of febrile neutropenia (FN) in patients who received urological anticancer chemotherapy. Methods: Between May 2005 and January 2010, 141 patients underwent urological anticancer chemotherapy at the Sapporo Medical University Hospital, Sapporo, Japan. They consisted of 124 men and 17 women aged 62 (range 16-80) years. The patients underwent a total of 626 treatment courses of urological anticancer chemotherapy. Results: Of the 626 urological anticancer chemotherapy courses, grades 3 and 4 neutropenia occurred in 451 (72.0%) courses. FN developed in 57 (9.1%) courses in which 7 (12.3%) and 50 (87.7%) patients were classified as high risk and low risk, respectively, according to the Multinational Association for Supportive Care in Cancer (MASCC) risk index scoring system. There was no anticancer chemotherapy-related death in either the high- or low-risk group. The frequencies of bacteria isolated from courses with FN were 0 and 10.0% for the high- and low-risk groups, respectively. Conclusions: According to the MASCC scoring system, there were fewer patients in the high-risk group than in the low-risk group in this study. There were no cases of anticancer chemotherapy-related death in either group. Therefore, urological anticancer chemotherapy can be conducted safely with the proper management of neutropenia and FN. Japan Society of Clinical Oncology, 2015 Febrile neutropenia nationallicence Urology nationallicence Anticancer chemotherapy nationallicence MASCC score nationallicence FN : Febrile neutropenia nationallicence MASCC : The Multinational Association for Supportive Care in Cancer risk index nationallicence G-CSF : Human granulocyte colony-stimulating factor nationallicence IDSA : Infectious Diseases Society of America nationallicence EORTC : The European Organisation for Research and Treatment of Cancer nationallicence GC : Gemcitabine and cisplatin nationallicence MVAC : Methotrexate, vinblastine, doxorubicin hydrochlorideand cisplatin nationallicence BEP : Bleomycin, etoposide and cisplatin nationallicence VeIP : Vinblastine, ifosfamide and cisplatin nationallicence TIN : Paclitaxel, ifosfamide and nedaplatin nationallicence DP : Docetaxel and prednisolone nationallicence Nishiyama Naotaka Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Takahashi Satoshi Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Mizuno Takahiro Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Uehara Teruhisa Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Hashimoto Jiro Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Kurimura Yuichirou Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut Masumori Naoya Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1012-1017 1341-9625 20:5<1012 2015 20 10147 https://doi.org/10.1007/s10147-015-0787-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0787-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nishiyama Naotaka Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Takahashi Satoshi Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Mizuno Takahiro Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Uehara Teruhisa Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Hashimoto Jiro Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Kurimura Yuichirou Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Masumori Naoya Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, 060-8543, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1012-1017 1341-9625 20:5<1012 2015 20 10147